EyeGene Inc (185490) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.061x

Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.13 Billion ≈ $-2.12 Million USD) by net assets (₩50.92 Billion ≈ $34.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 185490 market cap overview for the company's overall valuation and market capitalisation.

EyeGene Inc - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

EyeGene Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of EyeGene Inc to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Daebongls.Co.Ltd KQ:078140	-0.018x
Saga Communications Inc NASDAQ:SGA	0.003x
Samhwa Networks Co. Ltd KQ:046390	0.086x
Kayseri Seker Fabrikasi AS IS:KAYSE	0.171x
Xplus SA WAR:XPL	0.059x
TY Holdings Co Ltd KO:363280	-0.031x
General Commercial & Industrial S.A AT:GEBKA	0.044x
Polychem Indonesia Tbk JK:ADMG	-0.015x

Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2025. View current stock price of EyeGene Inc for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩54.25 Billion ≈ $36.77 Million	₩-5.98 Billion ≈ $-4.05 Million	-0.110x	+54.42%
2024-12-31	₩50.32 Billion ≈ $34.10 Million	₩-12.17 Billion ≈ $-8.25 Million	-0.242x	+22.45%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	₩-20.07 Billion ≈ $-13.60 Million	-0.312x	-12.09%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	₩-18.57 Billion ≈ $-12.58 Million	-0.278x	+17.49%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	₩-30.00 Billion ≈ $-20.33 Million	-0.337x	+55.40%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	₩-9.75 Billion ≈ $-6.61 Million	-0.756x	-72.94%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	₩-8.32 Billion ≈ $-5.64 Million	-0.437x	-36.42%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	₩-7.48 Billion ≈ $-5.07 Million	-0.321x	-12.64%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	₩-6.76 Billion ≈ $-4.58 Million	-0.285x	+23.06%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	₩-5.99 Billion ≈ $-4.06 Million	-0.370x	-87.96%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	₩-4.48 Billion ≈ $-3.04 Million	-0.197x	+68.29%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	₩-2.39 Billion ≈ $-1.62 Million	-0.621x	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$56.56 Million

₩83.46 Billion KRW

Market Cap Rank

#21537 Global

#1270 in Korea

Share Price

₩1931.00

Change (1 day)

+0.36%

52-Week Range

₩1193.00 - ₩2600.00

All Time High

₩50300.00